Drugs in ATC Class L01EJ

✉ Email this page to a colleague

« Back to Dashboard

Up to Top Level ATC Classes

Up to L - Antineoplastic and immunomodulating agents

Up to L01 - ANTINEOPLASTIC AGENTS

Up to L01E - PROTEIN KINASE INHIBITORS

Drugs in ATC Class: L01EJ - Janus-associated kinase (JAK) inhibitors drug patent expirations, market exclusivity, and generic launch dates

Glossary

Subscribe to access the full database, or Subscribe
Tradename	Generic Name
LEQSELVI	deuruxolitinib phosphate
OPZELURA	ruxolitinib phosphate
JAKAFI	ruxolitinib phosphate
INREBIC	fedratinib hydrochloride
VONJO	pacritinib citrate
OJJAARA	momelotinib dihydrochloride
>Tradename	>Generic Name

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.